Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2- Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02285114
Recruitment Status : Active, not recruiting
First Posted : November 6, 2014
Results First Posted : January 12, 2021
Last Update Posted : June 2, 2021
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences

Brief Summary:
The primary objective of this study is to confirm the TAF dose and to evaluate the pharmacokinetics (PK) of TAF, safety, and tolerability of F/TAF in HIV-1 infected children and adolescents virologically suppressed (defined as having < 50 copies/mL of HIV-1 ribonucleic acid [RNA] for a period of at least 6 months) while on a stable NRTI containing regimen.

Condition or disease Intervention/treatment Phase
HIV-1 Drug: F/TAF Drug: 3rd ARV agent Drug: Boosted PIs Phase 2 Phase 3

Detailed Description:

Cohorts 2, 3, and 4 will be on a boosted protease inhibitor (PI) or any other 3rd antiretroviral (ARV) agent and will switch their current 2-NRTI-containing regimen to open-label F/TAF while continuing their boosted PI or 3rd agent through 48 weeks. A minimum of 10 participants each in Groups 1 and 2 of Cohort 2, and Cohorts 3 and 4, who are on boosted-atazanavir (ATV) as their 3rd ARV agent will be enrolled. Participants in Cohort 2, Group 1 receive boosted PI agents only. Cohorts 2, 3, and 4 will be enrolled by cohort into a two-part study (Parts A and B).

After completion of 48 weeks, all participants will be given the option to participate in an extension phase of the study. Gilead will provide F/TAF until a) The participant turns 18 years old and F/TAF is commercially available for use in adults in the country in which the participant is enrolled or b), F/TAF becomes commercially available for pediatric use in the country in which the participant is enrolled or c), Gilead Sciences elects to terminate development of F/TAF in the applicable country.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 41 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2/3, Open-Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a 2-NRTI-Containing Regimen
Actual Study Start Date : January 20, 2015
Actual Primary Completion Date : November 4, 2019
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: F/TAF+3rd ARV agent (Cohort 1)
Participants between 12 to < 18 years of age and ≥ 35 kg in body weight will switch their current 2-NRTI containing regimen to F/TAF (200/25 mg for unboosted 3rd agent and 200/10 mg for boosted 3rd agent) while continuing on their 3rd ARV agent for 48 weeks.
Drug: F/TAF
F/TAF tablets administered orally once daily

Drug: 3rd ARV agent
A 3rd antiretroviral (ARV) agent of the participant's pre-existing regimen may include one of the following: boosted atazanavir (ATV), boosted lopinavir (LPV), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG).

Experimental: F/TAF+3rd ARV agent (Cohort 2, Group 1, Part A)
Participants between 6 to < 12 years of age and ≥ 25 kg in body weight must be on a boosted protease inhibitor (PI) as their 3rd ARV agent and will switch their current 2-NRTI regimen to F/TAF 200/25 mg while continuing on their boosted PI for 48 weeks.
Drug: F/TAF
F/TAF tablets administered orally once daily

Drug: Boosted PIs
Boosted PIs of the participant's pre-existing regimen may include one of the following: ATV, LPV, or DRV.

Experimental: F/TAF+3rd ARV agent (Cohort 2, Group 2, Part A)
Participants between 2 to < 12 years of age and between 17 kg to < 25 kg in body weight must be on a boosted protocol specified 3rd ARV agent and will switch their current 2-NRTI containing regimen to F/TAF 120/15 mg while continuing their 3rd ARV agent for 48 weeks.
Drug: F/TAF
F/TAF tablets administered orally once daily

Drug: 3rd ARV agent
A 3rd antiretroviral (ARV) agent of the participant's pre-existing regimen may include one of the following: boosted atazanavir (ATV), boosted lopinavir (LPV), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG).

Experimental: FTC/TAF+3rd ARV agent (Cohort 3, Part A)
Participants between 2 to < 6 years of age will receive F/TAF plus a 3rd ARV agent through 48 weeks.
Drug: F/TAF
F/TAF tablets administered orally once daily

Drug: 3rd ARV agent
A 3rd antiretroviral (ARV) agent of the participant's pre-existing regimen may include one of the following: boosted atazanavir (ATV), boosted lopinavir (LPV), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG).

Experimental: FTC/TAF+3rd ARV agent (Cohort 4, Part A)
Participants between 1 month to < 2 years of age will receive F/TAF plus a 3rd ARV agent through 48 weeks.
Drug: F/TAF
F/TAF tablets administered orally once daily

Drug: 3rd ARV agent
A 3rd antiretroviral (ARV) agent of the participant's pre-existing regimen may include one of the following: boosted atazanavir (ATV), boosted lopinavir (LPV), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG).

Experimental: F/TAF+3rd ARV agent (Cohort 2, Group 1, Part B)
Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
Drug: F/TAF
F/TAF tablets administered orally once daily

Drug: 3rd ARV agent
A 3rd antiretroviral (ARV) agent of the participant's pre-existing regimen may include one of the following: boosted atazanavir (ATV), boosted lopinavir (LPV), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG).

Experimental: F/TAF+3rd ARV agent (Cohort 2, Group 2, Part B)
Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
Drug: F/TAF
F/TAF tablets administered orally once daily

Drug: 3rd ARV agent
A 3rd antiretroviral (ARV) agent of the participant's pre-existing regimen may include one of the following: boosted atazanavir (ATV), boosted lopinavir (LPV), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG).

Experimental: FTC/TAF+3rd ARV agent (Cohort 3, Part B)
Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
Drug: F/TAF
F/TAF tablets administered orally once daily

Drug: 3rd ARV agent
A 3rd antiretroviral (ARV) agent of the participant's pre-existing regimen may include one of the following: boosted atazanavir (ATV), boosted lopinavir (LPV), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG).

Experimental: FTC/TAF+3rd ARV agent (Cohort 4, Part B)
Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
Drug: F/TAF
F/TAF tablets administered orally once daily

Drug: 3rd ARV agent
A 3rd antiretroviral (ARV) agent of the participant's pre-existing regimen may include one of the following: boosted atazanavir (ATV), boosted lopinavir (LPV), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG).

Experimental: FTC/TAF +3rd ARV agent (Extension Phase)
After completion of 48 weeks, all participants will be given the option to participate in an extension phase of the study. Gilead will provide F/TAF until a) the participant turns 18 and F/TAF is commercially available for use in adults in the country in which the participant is enrolled or, b) F/TAF becomes commercially available for pediatric use in the country in which the participant is enrolled or, c) Gilead Sciences elects to terminate development of F/TAF in the applicable country.
Drug: F/TAF
F/TAF tablets administered orally once daily

Drug: 3rd ARV agent
A 3rd antiretroviral (ARV) agent of the participant's pre-existing regimen may include one of the following: boosted atazanavir (ATV), boosted lopinavir (LPV), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG).




Primary Outcome Measures :
  1. Pharmacokinetic (PK) Parameter (Cohort 1): AUCtau of Tenofovir Alafenamide (TAF) [ Time Frame: Any time at Week 2 visit ]
    AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).

  2. PK Parameter (Cohort 2): AUCtau of TAF [ Time Frame: Any time at Week 2 or Week 4 visit, or within 7 days after the completion of Week 2 or Week 4 visits ]
    AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).

  3. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Through Week 24 [ Time Frame: Baseline through Week 24 ]
    An AE is any untoward medical occurrence in a clinical study participant which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The TEAEs were defined as any AEs with an onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug.


Secondary Outcome Measures :
  1. PK Parameter (Cohort 1): Cmax of TAF, FTC, and TFV [ Time Frame: Any time at Week 2 visit ]
    Cmax is defined as the maximum concentration of drug.

  2. PK Parameter (Cohort 2): Cmax of TAF, FTC, and TFV [ Time Frame: Any time at Week 2 or Week 4 visit, or within 7 days after the completion of Week 2 or Week 4 visits ]
    Cmax is defined as the maximum concentration of drug.

  3. PK Parameter (Cohort 1): Clast of TAF [ Time Frame: Any time at Week 2 visit ]
    Clast is defined as the last observable concentration of drug.

  4. PK Parameter (Cohort 2) : Clast of TAF [ Time Frame: Any time at Week 2 or Week 4 visit, or within 7 days after the completion of Week 2 or Week 4 visits ]
    Clast is defined as the last observable concentration of drug.

  5. PK Parameter (Cohort 1): CL/F of TAF [ Time Frame: Any time at Week 2 visit ]
    CL/F is defined as the apparent oral clearance following administration of the drug.

  6. PK Parameter (Cohort 2): CL/F of TAF [ Time Frame: Any time at Week 2 or Week 4 visit, or within 7 days after the completion of Week 2 or Week 4 visits ]
    CL/F is defined as the apparent oral clearance following administration of the drug.

  7. PK Parameter (Cohort 1): Vz/F of TAF [ Time Frame: Any time at Week 2 visit ]
    Vz/F is defined as the apparent volume of distribution of the drug.

  8. PK Parameter (Cohort 2): Vz/F of TAF [ Time Frame: Any time at Week 2 or Week 4 visit, or within 7 days after the completion of Week 2 or Week 4 visits ]
    Vz/F is defined as the apparent volume of distribution of the drug.

  9. PK Parameter (Cohort 1): AUCtau of FTC and TFV [ Time Frame: Any time at Week 2 visit ]
    AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).

  10. PK Parameter (Cohort 2): AUCtau of FTC and TFV [ Time Frame: Any time at Week 2 or Week 4 visit, or within 7 days after the completion of Week 2 or Week 4 visits ]
    AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).

  11. PK Parameter (Cohort 1): Ctau of FTC and TFV [ Time Frame: Any time at Week 2 visit ]
    Ctau is defined as the observed drug concentration at the end of the dosing interval.

  12. PK Parameter (Cohort 2): Ctau of FTC and TFV [ Time Frame: Any time at Week 2 or Week 4 visit, or within 7 days after the completion of Week 2 or Week 4 visits ]
    Ctau is defined as the observed drug concentration at the end of the dosing interval.

  13. Percentage of Participants Experiencing TEAEs and SAEs Through Week 48 [ Time Frame: Baseline through Week 48 ]
    An AE is any untoward medical occurrence in a clinical study participant which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The TEAEs were defined as any AEs with an onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug.

  14. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm [ Time Frame: Week 24 ]
    The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

  15. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the US FDA-Defined Snapshot Algorithm [ Time Frame: Week 48 ]
    The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

  16. Change From Baseline in CD4+ Cell Count at Week 24 [ Time Frame: Baseline, Week 24 ]
  17. Change From Baseline in CD4+ Cell Count at Week 48 [ Time Frame: Baseline, Week 48 ]
  18. Change From Baseline in CD4 Percentage at Week 24 [ Time Frame: Baseline, Week 24 ]
  19. Change From Baseline in CD4 Percentage at Week 48 [ Time Frame: Baseline, Week 48 ]
  20. Percentage of Participants With Palatability of F/TAF Formulation [ Time Frame: Week 2 (for Cohort 1), Week 2 and Week 4 (for Cohort 2) ]
    Palatability was reported based on the product taste of being normal or abnormal. Missing data were reported separately.

  21. Percentage of Participants With Acceptability of F/TAF Formulation [ Time Frame: Baseline up to Week 4 ]
    Acceptability was reported based on the the product size and shape. Missing data were reported separately.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Month to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • HIV-1 infected male and female adolescents and children aged 1 month to < 18 years at baseline/Day 1 (according to requirements of the enrolling cohort)
  • Must be able to give written assent prior to any screening evaluations
  • Parent or guardian able to give written informed consent prior to any screening evaluations and willing to comply with study requirements
  • Body weight at screening as follows:

    • Cohort 1: ≥ 35 kg
    • Cohort 2, Group 1: ≥ 25 kg
    • Cohort 2, Group 2: 17 kg to < 25 kg
    • Cohort 3: to be updated per a protocol amendment
    • Cohort 4: to be updated per a protocol amendment
  • Currently on a stable 2-NRTI containing regimen that includes a 3rd ARV agent for ≥ 6 consecutive months prior to screening
  • Plasma HIV-1 RNA levels < 50 copies/mL for ≥ 6 consecutive months preceding the screening visit
  • No opportunistic infection within 30 days of study entry (at baseline/Day 1)
  • A negative serum β-human chorionic gonadotropin (HCG) pregnancy test is required for females of childbearing potential only

Key Exclusion Criteria:

  • An acquired immunodeficiency syndrome (AIDS) - indicator condition with onset within 30 days prior to screening
  • Life expectancy of < 2 years
  • Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to baseline/Day 1
  • Evidence of active pulmonary or extra-pulmonary tuberculosis disease within 3 months of the screening visit
  • Active hepatitis C virus (HCV) infection defined as positive for HCV antibody and having detectable HCV RNA
  • Positive hepatitis B surface antigen or other evidence of active hepatitis B virus (HBV) infection.
  • Have any serious or active medical or psychiatric illness which, in the opinion of the Investigator, would interfere with treatment, assessment, or compliance with the protocol.
  • Pregnant or lactating females
  • Have history of significant drug sensitivity or drug allergy
  • Have previously participated in an investigational trial involving administration of any investigational agent, other than tenofovir, within 30 days prior to the study dosing

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02285114


Locations
Layout table for location information
United States, California
University of California Los Angeles
Los Angeles, California, United States, 90095
United States, Colorado
Children's Hospital Colorado
Aurora, Colorado, United States, 80045
United States, Pennsylvania
St. Christopher's Hospital for Children
Philadelphia, Pennsylvania, United States, 19134
United States, Washington
Seattle Children's Hospital
Seattle, Washington, United States, 98105-0371
Panama
Hospital del Nino
Panama City, Panama, 0816-00383
South Africa
Rahima Moosa Mother and Child Hospital
Johannesburg, Coronationville, South Africa, 2093
KIDCRU, Ward J8, Tygerberg Children's Hospital
Cape Town, South Africa, 7505
Be Part Yoluntu Centre
Cape Town, South Africa, 7626
Sponsors and Collaborators
Gilead Sciences
Investigators
Layout table for investigator information
Study Director: Gilead Study Director Gilead Sciences
  Study Documents (Full-Text)

Documents provided by Gilead Sciences:
Study Protocol  [PDF] August 2, 2017
Statistical Analysis Plan  [PDF] October 6, 2020

Layout table for additonal information
Responsible Party: Gilead Sciences
ClinicalTrials.gov Identifier: NCT02285114    
Other Study ID Numbers: GS-US-311-1269
2015-001339-19 ( EudraCT Number )
First Posted: November 6, 2014    Key Record Dates
Results First Posted: January 12, 2021
Last Update Posted: June 2, 2021
Last Verified: May 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Gilead Sciences:
emtricitabine
FTC
tenofovir
TDF
antiretroviral
adolescents
children
pediatric